Brief: VBL Therapeutics Says Data Safety Monitoring Committee Provides Green Light To Advance Oval Phase 3 Registration Enabling Study Of Vb-111 In Ovarian Cancer

Notable Labs

22/02/2021 12:05

Feb 22 (Reuters) - Vascular Biogenics Ltd  VBLT.O :
    * VBL THERAPEUTICS ANNOUNCES DATA SAFETY MONITORING
COMMITTEE
PROVIDES GREEN LIGHT TO ADVANCE THE OVAL PHASE 3 REGISTRATION
ENABLING STUDY OF VB-111 IN OVARIAN CANCER
    * VASCULAR BIOGENICS LTD - COMMITTEE FOUND NO SAFETY ISSUES
WITH
TRIAL AND RECOMMENDED ITS CONTINUATION AS PLANNED.
    * VASCULAR BIOGENICS LTD - TRIAL CONTINUES TO ENROLL ON
TRACK IN
US, EUROPE AND ISRAEL

Source text for Eikon:  ID:nGNX5VyGsV 
Further company coverage:  VBLT.O 

 ((Reuters.Briefs@thomsonreuters.com;))